CSTL stock icon

Castle Biosciences

33.29 USD
-0.02
0.06%
At close Nov 8, 4:00 PM EST
After hours
34.00
+0.71
2.13%
1 day
-0.06%
5 days
2.24%
1 month
10.93%
3 months
19.58%
6 months
41.42%
Year to date
51.59%
1 year
85.36%
5 years
50.77%
 

About: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Employees: 703

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

326% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $2.83M

300% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]

33% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 24

15% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 48

5% more funds holding

Funds holding: 150 [Q1] → 158 (+8) [Q2]

5% less capital invested

Capital invested by funds: $581M [Q1] → $553M (-$27.6M) [Q2]

3.39% less ownership

Funds ownership: 95.49% [Q1] → 92.1% (-3.39%) [Q2]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$36
8%
upside
Avg. target
$40
21%
upside
High target
$44
32%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Scotiabank
Sung Ji Nam
65% 1-year accuracy
13 / 20 met price target
32%upside
$44
Sector Outperform
Maintained
6 Nov 2024
Lake Street
Thomas Flaten
50% 1-year accuracy
4 / 8 met price target
20%upside
$40
Buy
Maintained
5 Nov 2024
Keybanc
Paul Knight
50% 1-year accuracy
4 / 8 met price target
8%upside
$36
Overweight
Maintained
5 Nov 2024
Baird
Catherine Ramsey
88% 1-year accuracy
7 / 8 met price target
17%upside
$39
Outperform
Maintained
5 Nov 2024
Canaccord Genuity
Kyle Mikson
59% 1-year accuracy
10 / 17 met price target
26%upside
$42
Buy
Maintained
29 Oct 2024

Financial journalist opinion

Based on 19 articles about CSTL published over the past 30 days

Charts implemented using Lightweight Charts™